ISSN: 1743-7555

Journal Home

Journal Guideline

Asia-Pacific Journal of Clinical Oncology Q2 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Asia-Pacific Journal of Clinical Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 41. It has a price of 2395 €. It has an SJR impact factor of 0,531 and it has a best quartile of Q2. It has an SJR impact factor of 0,531.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q2) Oncology (Q3)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Asia-Pacific Journal of Clinical Oncology

0,531

SJR Impact factor

41

H Index

182

Total Docs (Last Year)

401

Total Docs (3 years)

6527

Total Refs

672

Total Cites (3 years)

385

Citable Docs (3 years)

1.82

Cites/Doc (2 years)

35.86

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer

Challenging patient populations in breast cancer: Taxane resistance and triple-negative receptor subtype

Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation: Perspective and lessons from a tertiary care institution in India

Hypofractionated versus standard fractionation radiotherapy in early glottic cancer: A retrospective review

Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia's largest study

Welcome Message from Conference Co-Convenors

Result of extracorporeal irradiation and re-implantation for malignant bone tumors: A review of 30 patients

Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care

About the Cancer Research Network

Aflibercept-related nasal septum perforation

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib

Use of non-anthracycline regimens in early stage breast cancer in Australia

SHOW MORE ARTICLES

Metastatic gastric cancer: Does the site of metastasis make a difference?

Cholangiocarcinoma in USA- versus Asian-born Asians: Is viral hepatitis a factor?

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

Breast Cancer in the Asia-Pacific Region

Advanced renal cell carcinoma in Australia, 2015: What should we do?

Factors related to sexual health in Chinese women with breast cancer in Hong Kong

Effect of the allelic variants ofABCB1, CYP2D6andHTR3Bon response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients

Simultaneous comparison of multiple molecules using tissue array analysis in the thyroid neoplasm

Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review

When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival

Medium-dose-rate brachytherapy for cancer of the cervix: Preliminary results of a designed schedule

Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection